What is the recommended management for triple‑negative breast cancer (TNBC) in early‑stage (non‑metastatic) and metastatic settings, including chemotherapy regimens, immunotherapy, targeted therapy, and radiation?

Management of Triple Negative Breast Cancer

Early-Stage (Non-Metastatic) TNBC

For patients with stage II-III TNBC, the standard neoadjuvant regimen is pembrolizumab combined with paclitaxel, carboplatin, doxorubicin, and cyclophosphamide (KEYNOTE-522 regimen), followed by adjuvant pembrolizumab after surgery. This approach achieves pathologic complete response (pCR) rates of 65% and significantly improves event-free survival 1.

Neoadjuvant Therapy Options

• Standard regimen (KEYNOTE-522): Pembrolizumab + paclitaxel + carboplatin + doxorubicin + cyclophosphamide

  • pCR rate: 65% vs 51% with chemotherapy alone
  • Continue pembrolizumab adjuvantly for up to 1 year regardless of pathologic response 1

• Anthracycline-free alternative (NeoPACT regimen): Pembrolizumab + carboplatin + docetaxel for 6 cycles

  • pCR rate: 58% overall (65% in node-negative, 45% in node-positive disease)
  • 3-year event-free survival: 86%
  • Use this regimen only for patients who cannot receive anthracyclines or have early-stage disease without axillary lymph node involvement 1
  • Do NOT use routinely as a substitute for KEYNOTE-522, especially in node-positive disease where anthracycline-containing regimens remain superior 1

Adjuvant Therapy for Residual Disease

For patients with residual disease after neoadjuvant chemo-immunotherapy:

• Consider adding capecitabine during the adjuvant pembrolizumab phase, as it has demonstrated survival benefit in patients with residual disease after neoadjuvant chemotherapy and appears safe when combined with pembrolizumab 2

• For germline BRCA mutation carriers with residual disease: Olaparib combined with pembrolizumab is an option based on safety data 2

---

Metastatic TNBC

First-Line Therapy

PD-L1 Positive Disease (≥1% by SP142 or CPS ≥10 by 22C3):

Add immune checkpoint inhibitor to chemotherapy as first-line treatment 3:

• Atezolizumab + nab-paclitaxel (IMpassion130: median OS 25 vs 18 months)
• Pembrolizumab + chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin)

This combination improves both progression-free survival (PFS 7.5 vs 5 months) and overall survival (OS 25 vs 15.5 months) 3.

PD-L1 Negative Disease:

Use single-agent chemotherapy rather than combination chemotherapy 3. Choose between:

• Platinum-based agents (carboplatin, cisplatin)
• Non-platinum agents (taxanes, capecitabine, eribulin, gemcitabine, vinorelbine)

Exception: Use combination chemotherapy only for symptomatic or immediately life-threatening visceral crisis where there may be only one chance for response 3.

Second-Line and Beyond

After ≥2 prior therapies for metastatic disease:

Sacituzumab govitecan is the preferred treatment (high-quality evidence, strong recommendation) 3.

BRCA Mutation Carriers

For germline BRCA1/2 mutation carriers who have received prior chemotherapy (neoadjuvant, adjuvant, or metastatic):

Offer oral PARP inhibitors (olaparib or talazoparib) rather than chemotherapy 3. These agents demonstrate high response rates and can be used in first- through third-line settings.

Important caveat: PARP inhibitor trials did not directly compare against taxanes, anthracyclines, or platinums, so comparative efficacy against these specific agents is unknown 3. PARP inhibitors also show activity in germline PALB2 mutation carriers and somatic BRCA mutations 3.

---

Key Clinical Considerations

Treatment Sequencing Algorithm

1. Test PD-L1 status and BRCA mutation status at diagnosis
2. First-line metastatic:
   • PD-L1 positive → Immunotherapy + chemotherapy
   • PD-L1 negative → Single-agent chemotherapy
   • BRCA mutated (any PD-L1 status) → Consider PARP inhibitor
3. After progression on ≥2 lines → Sacituzumab govitecan

Common Pitfalls

• Do not routinely substitute the NeoPACT anthracycline-free regimen for KEYNOTE-522 in node-positive disease—anthracycline-containing regimens remain more effective 1

• Do not use combination chemotherapy in PD-L1-negative metastatic disease unless facing visceral crisis 3

• Resistance to chemotherapy develops quickly in metastatic TNBC; lines of treatment beyond second-line show diminishing returns 3

• Immune-related adverse events occur in approximately 10% of patients on checkpoint inhibitors, with thyroid disease in 23% 3

Radiation Therapy

While not extensively detailed in the provided guidelines, radiation therapy remains an integral component of locoregional management for early-stage TNBC following surgery, particularly for patients with node-positive disease or those who undergo breast-conserving surgery.